KRT5 and breast cancer: Rakha and coworkers have explored this important topic by studying two large cohorts of breast cancer patients with a large panel of biomarkers to explore the clinicopathologic differences that exist between TNBCs that express one or more of basal markers and defined as BLBC (such as cytokeratin, CK, CK5/6, CK17, CK14, and EGFR, about 70%) and TNBCs that do not express these markers, being defined as TNBCKE- (about 30%) [109].